Induction of new antigenic properties on DTIC-treated L1210 clones.
In vivo treatment of mouse leukemia L1210 with DTIC can induce new antigens on tumor cells that are not detectable on parental cells and that are transmissible as a genetic character. Moreover, L1210/DTIC is rejected by syngeneic hosts. The aim of this study was to investigate whether DTIC selects pre-existing immunogenic clones rather than inducing ex novo new antigenic determinants and to verify the number of induced antigens. L1210 leukemia was cloned in vitro and 4 clones were treated in vivo with DTIC. All the treated clones displayed antigenic properties since they were rejected by syngeneic hosts. Cytotoxic T lymphocytes (CTL) activated against one DTIC clone could recognize and lyse the relevant target. One of these DTIC-modified clones (L4/DTIC) was recloned and the subclones were tested in vivo and in vitro. Two out of six subclones were rejected by syngeneic hosts. CTL specific against these two clones were able to recognize and lyse all the other clones to different degrees. The degree of susceptibility to lysis did not correlate with the capability to evoke an immune response in vivo. Based on these findings we conclude that DTIC does not select pre-existing clones but modifies the tumor cells antigenically, and that the antigenicity induced by DTIC in a cloned tumor line is due to the presence of common antigens shared to different degrees with treated cells.
Marelli
O
O
Department of Pharmacology, School of Medicine, Università di Milano, Italia.
Franco
P
P
Canti
G
G
Prandoni
N
N
Ricci
L
L
D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis*; D002460:Cell Line; D002999:Clone Cells / Q000187:drug effects; D003429:Cross Reactions; D003606:Dacarbazine / Q000494:pharmacology*; D005260:Female; D007939:Leukemia L1210 / Q000276:immunology* / Q000473:pathology; D008297:Male; D051379:Mice; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects
D000951:Antigens, Neoplasm; D003606:Dacarbazine